The devices, currently being investigated by teams of heart specialists, could make a big impact in the years ahead. 

New data from the STROKE AF clinical trial shows large and small vessel ischemic stroke patients who receive short-term or intermittent monitoring with Holter and 30-day external monitors had fewer AFib episodes detected that continuous implantable cardiac monitors.

The FDA’s approval was based on data from the EXPLORER-HCM trial, which showed that mavacamten was superior to a placebo for treating obstructive HCM and associated with no significant long-term, treatment-related adverse events.

Heart Rhythm 2022, held from April 28 to May 1 in San Francisco, included a wide range of studies presented by some of the industry's leading specialists. 

It has been a busy few weeks for the FDA, with plenty of big-name approvals and recalls making the news, but there have also been some other big announcements related to solutions receiving FDA clearance. 

The results of a study published in Radiology: Cardiothoracic Imaging call into question the value of initiating aspirin therapy in certain instances.

A large proportion of patients with atrial fibrillation (AFib) end up in emergency rooms (ERs), but there are inherent issues with most hospital ERs handing off these patients to electrophysiologists for follow-up care.

The FDA and Medtronic warn some Heartware Ventricular Assist Device (HVAD) systems have a defect that may cause pump thrombosis.

A team of researchers used computer science and mathematics to study the "triple whammy" of diuretics, RAS inhibitors and NSAIDs.

A technique seen in the Pfizer-BioNTech and Moderna COVID-19 vaccines may be able to help heart cells repair themselves, according to new research out of the Netherlands.